Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2012

Feb 17, 2012

151_ip_2012-02-17_bc6dc19f-896a-438e-a4f3-7bcd9417b61e.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Fight Cancer! Eine Initiative der Deutschen Biotechnologie

Evotec: Partner of Choice in Oncology Drug Discovery

Dr. Cord Dohrmann, Chief Scientific Officer

•Evotec at a glance

  • • Experience and current oncology partners
  • • Examples of cancer allia ances
  • • Opportunities with Evote ec

Leader in high qua ality drug discovery solutions

Evotec at a glance 1)

2 1) Founded in 1993, Publicly listed on TecDAX (Germany) ), approx. 70% free float, >600 employees, Headquarter in Hamburg, Germany

Global reach for g approx. 600 scient lobal p j ro ects – tists

Evotec worldwide

Sales representation (Boston, Tokyo) Operations & sales representation

Drug discovery alliances & more

Our alliance model in drug discovery and product development

Best-in-class platf forms yield superior productivity

"EVO Discover" – Best froom target to IND

Key strength y g

  • Complete value chain, with all value creating steps in house (>100 lead series, >50 pre-clinical, 1( 00 ead se es, 50 p e c ca ,and clinical candidates)
  • Proven target ID platform focusing on disease modifying mechanisms regenerating and protecting 2 , key tissues and cell types
  • Industry leader in HTS and other platforms (e.g. FBDD, HCS, d th3compound management, chemoproteomics, phosphoproteomics) 2)
  • High quality medicinal chemistry, supported by leading SGDD 3) and 4computational chemistry

  • Comprehensive compound profiling 5

  • 5 1) PDC … Preclinical Development Candidate

  • 2) HTS … High throughput screening; FBBD … Fragment--based Drug Discovery (EVOlution); HCS … High Content Screening
  • 3) SGDD … Structure based drug design

Deep clinical pipel line without financial risk

Portfolio of product develo opment partnerships

i
i
I
d
t
n
c
a
o
n		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 i
U
d
p
s
e
e
f
E
t
t
o
r
o
e
c
v		 N
t
e
x
i
l
t
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
)
1
D
i
b
t
a
e
e
s		 P
h
I
I
I
a
s
e		 +
+
+		 F
i
l
P
h
I
I
I
d
t
n
a
a
s
e
a
a		 M
i
l
l
i
t
t
e
s
o
n
e
s
r
o
y
a
e
s
;
,
i
l
k
t
t
t
p
o
e
n
a
m
a
r
e
a
p
p
r
o
x
€
5
0
0
m
A
l
h
i
e
m
e
r
s
z
D
i
s
e
a
s
e		 P
h
I
I
a
s
e		 +
+
+
+
+
+		 P
h
I
I
b
i
i
i
i
t
t
a
s
e
n
a
o
n		 M
M
i
i
l
l
l
i
t
t
t
e
e
s
s
o
o
n
n
e
e
s
s
r
o
a
e
s
y
;
,
i
l
k
t
t
t
p
o
e
n
a
m
a
r
e
a
p
p
r
o
x
€
3–
b
5
n
T
i
t
t
t
t
r
e
a
m
e
n
r
e
s
s
a
n
d
i
e
p
r
e
s
s
o
n		 O
p
e
n		 P
h
I
I
a
s
e		 +
+
+		 N
i
t
e
p
a
r
n
e
r
n
g
w		 O
p
e
n
2
)
I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 +
+		 P
h
I
I
b
t
t
a
s
e
s
a
r		 M
i
l
l
i
t
t
e
s
o
n
e
s
r
o
a
e
s
y
,
I
f
l
i
i
t
n
a
m
m
a
o
n
n
)
3
i
l
h
l
h
t
a
n
m
a
e
a		 /
P
h
I
I
I
a
s
e		 +
+
+		 P
h
I
I
t
t
a
s
e
s
a
r		 M
i
l
l
i
t
t
e
s
o
n
e
s
r
o
a
e
s
y
,
O
l
n
c
o
o
g
y		 P
l
i
i
l
r
e
-c
n
c
a		 +
+		 P
i
t
a
r
n
e
r
n
g		 M
i
l
l
i
t
t
e
s
o
n
e
s
r
o
a
e
s
y
,

6 1) DiaPep277 is being developed by Andromeda Biotech L Ltd and has been partnered with TEVA Pharmaceuticals Industries Ltd

2) Chinese rights only; Safety and Phase IIb study planned d starting 2012

3) Animal Health (undisclosed)

4) EVT 501 (H3), P2X3, …

• Evotec at a glance

. Experience and current oncology partners

  • Examples of cancer alliances
  • Opportunities with Evotec

Productive oncoloogy platform

Wide spectrum of mechan nisms and target classes

M
h
i
e
c
a
n
s
m
s		 T
t
a
r
g
e
s
S
i
l
d
i
t
t
g
n
a
r
a
n
s
u
c
o
n		 A
k
/
/
P
P
K
K
B
B
A
A
l
l
k
k-
d
C
C
K
K
A
C
C
H
H
K
K
/
/
P
P
l
l
k
k-
3
5
5
2
2
1
1
2
2
2
t
a
n
u
r
o
o
o
r
r
a
a
-
,
,
,
,
,
,
b
R
f,
M
S
E
k,
C
D
K
k
i
K
D
R
t,
a
c-
e
c-
r
c
r
a
r
o
r
a
n
a
s
e
u
u
-
,
,
,
,
H
S
P
9
0
T
b
l
i
t
u
m
o
r
m
e
a
o
s
m		 P
k
i
M
1
d
d
M
M
2
2
l
D
D
H
H
i
i
t
t
t
t
t
t
y
r
u
v
a
e
n
a
s
e
a
a
n
n
a
c
a
e
s
o
c
r
a
e
,
,
d
h
d
e
y
r
o
g
e
n
a
s
e
T
i
t
t
u
m
o
r
m
e
a
s
a
s
s
d
l
i
i
t
a
n
v
a
s
c
u
a
r
s
a
o
n		 M
M
P
h
i
i
i
i
d
t
t
s
m
e
o
n
n
e
a
m
n
o
p
e
p
a
a
s
e
,
A
i
t
p
o
p
o
s
s		 B
l-
2
f
i
l
P
A
R
P
T
R
P
M
8
c
a
m
s
y,
,
E
i
i
t
p
g
e
n
e
c
s		 C
(
f
),
H
D
A
l
l
3
i
l
i
h
i
d
h
l
d
t
t
s
a
a
m
e
s
s
o
n
e
e
e
m
e
y
a
s
e
s
a
n
f
h
i
h
l
t
t
t
s
o
n
e
m
e
y
r
a
n
s
e
r
a
s
e
s
I
i
m
a
g
n
g
a
s
s
a
s
y		 C
l
l
l
i
f
i
l
l
d
h
i
i
i
i
d
t
t
t
t
t
e
p
r
o
e
r
a
o
n
c
e
e
a
a
p
o
p
p
o
s
s
m
o
c
n
e
x
,
,
,
,
b
i
k
o
m
a
r
e
r
s

Delivered 5 clinical candidates and 3 clinical stage compounds

Current oncology alliances

Highly flexible arrangeme ents – optimal fit for customer and project

i
D
d
t
r
g
s
c
o
e
r
p
a
r
n
e
r
s
u
v
y		 f
j
N
b
P
t
m
m
e
r
o
r
o
e
c
s
u		 i
i
E
b
t
t
t
o
e
c
c
o
n
r
o
n
v
u
B
h
i
I
l
h
i
o
e
r
n
g
e
r
n
g
e
e
m		 M
l
i
l
t
u
p
e		 I
d
t
t
n
e
g
r
a
e
G
h
t
e
n
e
n
e
c		 M
l
i
l
t
u
p
e		 I
d
t
t
n
e
g
r
a
e
D
i
i
h
i
a
c		 M
l
i
l
t
u
p
e		 P
f
i
l
i
r
o
n
g
T
k
d
a
e
a		 S
i
l
n
g
g
e		 P
f
i
l
i
r
o
n
g
E
i
p
m
e
z
y		 S
i
l
n
g
g
e		 I
d
t
t
n
e
g
r
a
e
O
h
t
n
c
o
e
r
a
p
y		 S
i
l
n
g
g
e		 I
d
t
t
n
e
g
r
a
e
A
i
B
i
h
t
t
c
e
o
e
c
v		 S
i
l
n
g
g
e		 I
d
t
t
n
e
g
r
a
e
i
B
k
d
l
t
o
m
a
r
e
r
e
e
o
p
m
e
n
v		 f
j
N
b
P
t
m
m
e
r
o
r
o
e
c
s
u		 i
i
E
b
t
t
t
o
e
c
c
o
n
r
o
n
v
u
R
h
o
c
e		 M
l
i
l
t
u
p
e		 P
h
h
t
o
s
p
o
s
c
o
u
A
b
i
t
m		 M
l
i
l
t
u
p
e		 P
h
h
t
o
s
p
o
s
c
o
u
T
h
i
l
U
i
i
M
i
h
t
e
c
n
c
a
n
e
r
s
n
c
v
y
u		 M
l
i
l
t
p
e
u		 P
h
h
t
o
s
p
o
s
c
o
u
  • •Evotec at a glance
  • • Experience and current oncology partners
  • • Examples of cancer all liances
  • Boehringer Ingelheim
  • Roche
  • • Opportunities with Evote ec

Boehringer Ingelh g Focus on cancereim-Alliance

Integrated oncology allian nce with Boehringer Ingelheim

K
l
e
g
o
a
s
y		 K
d
t
e
e
r
m
s
a
n
n
p
r
o
g
r
e
s
s
y
L
j
i
i
i
t
t
t
o
n
g
e
r
m
o
n
n
n
o
v
a
o
n
•
-
f
f
k
i
h
t
t
a
s
o
r
c
e
a
n
e
o
c
s
w
w
u
l
o
n
c
o
o
g
o
n
y
O
i
l
f
B
h
i
t
p
m
a
u
s
e
o
o
e
r
n
g
e
r
•
I
I
l
l
h
h
i
i
d
b
i
l
t
t
n
n
g
g
e
e
e
e
m
m
a
r
g
e
a
n
o
o
g
y
k
h
i
h
E
t
t
n
o
w
o
w
w
v
o
e
c
-
i
d
h
l
i
t
s
c
e
n
c
e
a
n
e
c
n
o
o
g
e
s
I
I
i
i
b
b
d
d
t
t
n
c
e
n
e
s
a
s
e
o
n
s
c
c
e
s
s
v
u
•
d
l
d
i
d
t
t
a
n
o
n
g
e
r
m
p
r
o
u
c
u
p
s
e
-		 S
d
d
d
d
2
0
0
4
t
t
t
t
a
r
e
a
n
e
x
e
n
e
o
•
d
2
0
1
3
e
n
f
f
T
F
T
E
E
d
t
e
a
m
o
s
r
o
m
o
e
c
a
n
v
•
B
I
f
f
f
f
R
R
h
h
d
d
i
i
E
E
t
t
e
s
e
a
r
c
n
n
n
g
o
r
o
e
c
u
v
•
F
T
E
s
S
i
i
f
i
i
l
d
t
t
g
n
c
a
n
m
e
s
o
n
e
s
a
n
•
l
i
d
t
r
o
a
p
s
e
e
y
y
u
M
i
l
h
i
d
1
5
t
t
e
s
o
n
e
s
s
a
c
e
e
o
v
•
d
d
d
i
t
t
5
a
a
e
e
c
o
m
p
p
o
n
n
s
;
;
u
d
l
d
2
i
h
l
i
i
t
t
e
e
o
p
m
e
n
a
n
n
e
c
n
c
v		 f
O
h
t
t
n
e
o
e
m
o
s
i
i
f
i
l
b
l
t
s
g
n
c
a
n
g
o
a
j
i
i
i
t
t
o
n
n
n
o
a
o
n
v
b
t
t
e
a
m
s
e
e
e
n
w
P
h
&
B
i
h
t
a
r
m
a
o
e
c

The future paradig gm in oncology

Biomarkers – Response Pr rediction – Personalized Medicine

Response prediction and biomarker discovery of targeted cancer drugs to support the development

Old Paradigm

Toxic, non-selective, chemotherapy drugs

Targeted T

Wider therape derived from biology disco '80seutic index, molecularveries of the

r Biology Molecular Profile

Therapies Future Paradigm

Integration of molecular diagnostics with targeted therapies for personalized cancer care

Phospho-signatur res as biomarkers

Phosphorylation state refl lects activity status of proteins/pathways

Roche oncology a alliance

A new approach to biomar rker development / response prediction

PhosphoScout

  • • Identification and quantification of cellular phosphoryla ation events by high end mass spectrometry

  • • Predicting favourable dosage and efficacy of targeted cancer drugs in patients

  • •Evotec at a glance

  • • Experience and current oncology partners
  • • Two example alliances
  • Boehringer Ingelheim
  • Roche
  • • Opportunities with Evo tec

Leveraging Evotec c expertise in oncology

Opportunities with Evotec c

i
f
f
i
i
i
K
l
t
t
n
a
s
e
r
r
s
s
n
-c
a
s
s
-
f
f
d
l
l
t
a
n
a
s
o
o
e
r
w
d
d
i
r
g
s
c
o
e
r
u
v
y		 E
i
i
t
t
t
p
g
e
n
e
c
a
r
g
e
s		 P
i
i
t
t
r
o
e
n
p
r
o
e
n
:
:
i
i
t
t
n
e
r
a
c
o
n
s		 i
P
h
t
e
n
o
p
c
s
c
r
e
e
n
s
y
i
j
i
i
h
t
t
n
c
o
n
n
c
o
n
u
w
C
l
l
l
T
t
e
a
r
a
r
g
e
u
P
f
i
l
i
r
o
n
g
L
K
i
A
f
f
i
i
t
e
v
e
r
a
g
e
n
n
y
•
d
S
B
d
t
t
a
n
r
c
r
e
a
s
e
u
u
D
D
i
l
f
t
r
g
e
s
g
n
p
a
o
r
m
s
u
A
l
h
i
h
t
t
p
p
g
c
o
n
e
n
y
•
i
i
d
/
m
a
g
n
g
a
n
o
r
M
l
e
s
o
s
c
a
e
h
l
i
t
e
c
n
o
o
g
e
s		 G
d
f
i
i
h
S
t
t
t
t
o
o
w
r
u
c
u
r
e
•
B
d
D
i
b
i
a
s
e
e
s
g
n
o

,
h
i
l
h
h
t
t
p
s
c
a
a
s
s
a
e
e
c
c
y
y

l
i
d
n
o
o
g
e
s
a
n
l
i
t
a
c
e
o
m
c
s
y		 R
i
l
d
i
t
a
o
n
a
e
e
s
g
n
•
h
d
b
i
a
p
p
r
o
a
c
e
s
a
n
o

h
i
l
i
p
s
c
a
s
c
r
e
e
n
n
g
y
t
r
o
e
s
u
M
S
l
f
t
a
s
s
p
e
c
p
a
o
r
m
•
l
l
i
i
t
t
r
e
e
a
s
m
p
r
o
e
n
v
u
l
b
l
i
c
o
m
p
e
a
s
s
e
m
e
s
x		 I
i
h
i
f
t
n
v
r
o
m
e
c
a
n
s
m
-o
•
i
d
i
t
t
a
c
o
n
s
e
s
u
P
i
l
f
t
t
o
e
n
a
o
r
•
d
i
f
f
i
d
i
l
i
t
t
e
r
e
n
a
e
p
p
e
n
e
h
a
p
p
r
o
a
c
O
t
t
p
e
n
s
a
r
g
e
s
p
a
c
e
•
d
h
h
i
t
a
n
e
n
c
e
c
e
m
s
r
y
s
p
a
c
e

Your contact:

Dr. Cord DohrmannChief Scientific Officer

+49.(0).40.560 81-241 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Regulatory Filings 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Regulatory Filings 2026
May 5
View all filings →